149 related articles for article (PubMed ID: 36162055)
1. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
2. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract][Full Text] [Related]
3. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
5. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
[TBL] [Abstract][Full Text] [Related]
6. A SNAI2/CTCF Interaction is Required for
Sreenivas P; Wang L; Wang M; Challa A; Modi P; Hensch NR; Gryder B; Chou HC; Zhao XR; Sunkel B; Moreno-Campos R; Khan J; Stanton BZ; Ignatius MS
Mol Cell Biol; 2023; 43(11):547-565. PubMed ID: 37882064
[TBL] [Abstract][Full Text] [Related]
7. SNAI2-Mediated Repression of
Wang L; Hensch NR; Bondra K; Sreenivas P; Zhao XR; Chen J; Moreno Campos R; Baxi K; Vaseva AV; Sunkel BD; Gryder BE; Pomella S; Stanton BZ; Zheng S; Chen EY; Rota R; Khan J; Houghton PJ; Ignatius MS
Cancer Res; 2021 Nov; 81(21):5451-5463. PubMed ID: 34462275
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
9. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway.
Hernandez KC; Shah AM; Lopez VA; Tagliabracci VS; Chen K; Xu L; Bassel-Duby R; Olson EN; Liu N
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2315925121. PubMed ID: 38227654
[TBL] [Abstract][Full Text] [Related]
10. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
12. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
13. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M
Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974
[TBL] [Abstract][Full Text] [Related]
14. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
[TBL] [Abstract][Full Text] [Related]
15. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
16. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract][Full Text] [Related]
18. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
[TBL] [Abstract][Full Text] [Related]
19.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
